Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.
作者信息
Albala David M
机构信息
Associated Medical ProfessionalsSyracuse, NY.
出版信息
Rev Urol. 2017;19(3):200-202. doi: 10.3909/riu193PracticeProfile.
Abstract
摘要
相似文献
1
Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.去势抵抗性前列腺癌患者的影像学检查及治疗建议
Rev Urol. 2017;19(3):200-202. doi: 10.3909/riu193PracticeProfile.
2
ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.ETS1 转录活性在晚期前列腺癌中增加，并促进去势抵抗表型。
Carcinogenesis. 2012 Mar;33(3):572-80. doi: 10.1093/carcin/bgs007. Epub 2012 Jan 9.
3
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.阿比特龙治疗后早期前列腺特异性抗原反应可预测转移性去势抵抗性前列腺癌的总生存期。
BMC Cancer. 2019 May 31;19(1):524. doi: 10.1186/s12885-019-5729-7.
4
Current perspectives on bone metastases in castrate-resistant prostate cancer.目前关于去势抵抗性前列腺癌骨转移的观点。
Cancer Metastasis Rev. 2018 Mar;37(1):189-196. doi: 10.1007/s10555-017-9719-4.
5
Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.自噬相关基因7（Atg7）与磷酸酶和张力蛋白同源物（Pten）缺失协同作用，促进前列腺癌肿瘤生长。
Genes Dev. 2016 Feb 15;30(4):399-407. doi: 10.1101/gad.274134.115.
6
Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer.循环游离核酸作为转移性去势抵抗性前列腺癌的预后和治疗预测工具
World J Clin Oncol. 2020 Jul 24;11(7):450-463. doi: 10.5306/wjco.v11.i7.450.
7
Potential role of rituximab in metastatic castrate-resistant prostate cancer.利妥昔单抗在转移性去势抵抗性前列腺癌中的潜在作用。
J Oncol Pharm Pract. 2019 Sep;25(6):1509-1511. doi: 10.1177/1078155218790338. Epub 2018 Aug 9.
8
Complete PSA Response Following Stereotactic Ablative Radiotherapy for a Bony Metastasis in the Setting of Castrate-Resistant Prostate Cancer.去势抵抗性前列腺癌伴骨转移患者接受立体定向消融放疗后的前列腺特异性抗原完全缓解
Cureus. 2015 Oct 26;7(10):e365. doi: 10.7759/cureus.365.
9
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8 T-cells Derived from Patients with Metastatic Castrate-resistant Disease.针对转移性去势抵抗性疾病患者来源的、前列腺特异性膜抗原特异性、转化生长因子-β 不敏感的基因靶向 CD8 T 细胞对人前列腺癌的疗效。
Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21.
10
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.多西他赛化疗用于中国去势抵抗性前列腺癌患者。
Hong Kong Med J. 2013 Jun;19(3):237-41. doi: 10.12809/hkmj133804. Epub 2013 Apr 3.
引用本文的文献
1
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer.达洛鲁胺在转移性去势抵抗性前列腺癌中的真实世界疗效
Endocr Relat Cancer. 2025 May 29;32(6). doi: 10.1530/ERC-24-0188. Print 2025 Jun 1.
2
Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.整合结构化和非结构化数据源，以识别和描述转移性去势抵抗性前列腺癌退伍军人中的遗传性癌症检测情况。
JCO Clin Cancer Inform. 2025 Feb;9:e2400189. doi: 10.1200/CCI-24-00189. Epub 2025 Feb 10.
3
Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach.基于甲基化的循环肿瘤DNA方法监测转移性前列腺癌治疗反应的可行性
Cancers (Basel). 2024 Jan 23;16(3):482. doi: 10.3390/cancers16030482.
4
Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines.经典型和截短型转谷氨酰胺酶-2 调节前列腺癌细胞系中黏蛋白-1 的表达和雄激素非依赖性。
Cell Death Dis. 2023 May 9;14(5):317. doi: 10.1038/s41419-023-05818-9.
5
Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.了解转移性去势抵抗性前列腺癌（mCRPC）患者在考虑治疗方案时关注的问题：一项美国患者偏好调查。
Cancer Med. 2023 Mar;12(5):6040-6055. doi: 10.1002/cam4.5313. Epub 2022 Oct 13.
6
Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.去势抵抗性转移性前列腺癌的预处理内脏转移：对疾病进展实际部位的预测与实际作用。
Cancer Imaging. 2022 Jul 14;22(1):34. doi: 10.1186/s40644-022-00469-z.
7
Imaging of Oligometastatic Disease.寡转移疾病的影像学检查
Cancers (Basel). 2022 Mar 10;14(6):1427. doi: 10.3390/cancers14061427.
8
HGK promotes metastatic dissemination in prostate cancer.HGK 促进前列腺癌的转移扩散。
Sci Rep. 2021 Jun 10;11(1):12287. doi: 10.1038/s41598-021-91292-2.
9
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.镭-223 与恩扎卢胺或阿比特龙/泼尼松同期或序贯治疗：转移性去势抵抗性前列腺癌患者的真实世界临床结局。
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):680-688. doi: 10.1038/s41391-020-0236-0. Epub 2020 May 13.
本文引用的文献
1
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).治疗分层在优化去势抵抗性前列腺癌患者治疗中的作用（前列腺癌影像学评估以检测晚期复发II）
Urology. 2017 Jun;104:150-159. doi: 10.1016/j.urology.2016.12.033. Epub 2017 Mar 14.
2
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.恩杂鲁胺治疗后，转移性去势抵抗性前列腺癌患者（此前接受多西他赛治疗）前列腺特异性抗原下降的临床结局和生存替代研究
Cancer. 2017 Jun 15;123(12):2303-2311. doi: 10.1002/cncr.30587. Epub 2017 Feb 7.
3
Sequencing of agents in castration-resistant prostate cancer.在去势抵抗性前列腺癌中对药物进行测序。
Lancet Oncol. 2015 Jun;16(6):e279-92. doi: 10.1016/S1470-2045(15)70033-1. Epub 2015 May 27.
4
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.恩扎卢胺对无症状和轻度症状、化疗初治转移性去势抵抗性前列腺癌（PREVAIL）患者健康相关生活质量、疼痛和骨骼相关事件的影响：一项随机、III 期试验的结果。
Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14.
5
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
6
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌治疗领域的变化。
Ther Adv Med Oncol. 2013 Jan;5(1):25-40. doi: 10.1177/1758834012458137.
7
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
Zotero 插件